🔗 Share this article

As the US continues making unprecedented revisions to its immunization guidelines, an unexpected name has emerged unexpectedly: Høeg, a US-based physician and public health researcher who rose to prominence by casting doubt on COVID-19 vaccines during the global health crisis and has concentrated on alleged deaths after Covid vaccination in her brief time at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Immunization Program

Health officials had intended to announce radical changes to the childhood immunization program recently, aligning the US with the Danish immunization schedule, it is understood – a significant shift that would place the US at odds with a large portion of the international standard with insufficient data for public health gain. The planned update has been pushed back until the coming year.

Instead of the director of the vaccine center, Høeg is listed to speak at the meeting. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to run the office this calendar year.

A New Direction at the Regulatory Body

The acting appointment could signify a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Prasad consolidate power at the regulatory agency – and it signals a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has frequently advocated for discontinuing specific pediatric vaccine recommendations in the US in order to be more like Denmark's approach, a country with comprehensive healthcare and a number of inhabitants roughly the population of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – traditionally the responsibility of Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Background

Dr. Høeg has no apparent experience in medication creation, regulation or management, which has been standard for past leaders of the CBER. She has worked at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for leading the CDER, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in managing a sizeable institution. She is not an expert in drug approvals.”

Former heads of CBER would “be deeply familiar with legal statutes and the research of medication creation”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who ran CBER have had.”

CDER has an immense range of responsibilities at the agency, the former commissioner pointed out.

“Many people just pays attention on the new drug program, but the off-patent medication office authorizes thousands of generic drugs. There’s a biosimilars program, non-prescription drug unit and more, and each of these need to be managed,” Woodcock explained. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial administrative element to the role, which manages more than 5,000 staff members. “It’s a huge leadership role, if you do it right,” she concluded.

Agency Reaction and Contentious Programs

When asked about concerns about Dr. Høeg's credentials and whether this assignment signifies more teamwork among regulatory chiefs on immunizations, a press secretary stated that the “concerns rely on incorrect presumptions”.

“Her resume is consistent with the responsibilities of her role,” the official said, pointing to the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg inherits the agency head's new priority voucher program, a disputed one-day drug-approval program that allegedly concerned her predecessors. “How are these medications being chosen for this fast-track system? Who makes the choices?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the FDA right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards laxer rules of all drugs, except for shots.”

Established Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a clearer, if problematic, track record, some experts have noted. She published a study using unverified crowd-sourced reports to assess the rate of heart inflammation after Covid immunization. She advised the state of Florida top health official Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccines are riskier than they are.

Included in her “policy goals” for the incoming federal leadership featured altering guidelines for recently developed shots and halting “optional” vaccines, she said post-election on a podcast. At the agency, Høeg has reportedly suggested preventing adolescent males from receiving COVID-19 vaccinations.

“She is an complete dogmatist who starts off with her beliefs and tailors the evidence to retrofit the science in a extremely misleading, fraudulent manner,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with fellow dissenters, {like|